A. Condoluci, Bellinzona (Switzerland), et al.
K. Fischer, Cologne (Germany), et al.
Authors Conclusion from the abstract: Fixed‐duration VenG induced deep, high (<10‐4 in 3/4 of pts and <10‐6 in 1/3 of pts), and long lasting MRD‐negativity rates (with a low rate of conversion to MRD‐positive status 1 year after treatment) in previously untreated pts with CLL and comorbidities, translating into improved PFS.
E. Tausch, Ulm (Germany), et al.
Authors Conclusion from the abstract: Prognostic value of genomic aberrations, IGHV and gene mutations were confirmed for G‐Clb, while with Ven‐G only del(17p) and TP53mut were associated with short PFS and only del(17p) with short OS. IGHVunmut was identified as a predictive factor identifying a group of patients with particular benefit from Ven‐G.
Best abstract submitted by a young investigator/travel grant recipient
P. Ghia, Milan (Italy), et al.
Authors Conclusion from the abstract: Acalabrutinib monotherapy significantly improved PFS with a more tolerable safety profile vs IdR/BR in pts with RR CLL.
W. Xu, Nanjing (China), et al.
Authors Conclusion from the abstract: Zanubrutinib was generally well‐tolerated and resulted in a high response rate, including in patients with del(17p) or TP53 mutation.
A.R. Mato, New York, NY (USA), et al.
Authors Conclusion from the abstract: Umbralisib is safe and effective in a KI intolerant CLL population. These are the first prospective data to confirm that switching from KI to Umbra can result in durable, well tolerated responses. From a therapy sequencing perspective, these data suggest use of an alternate KI is a reasonable strategy prior to class switch to a BCL‐2 inhibitor. Pre‐umbralisib dosing samples are being analyzed for CYP‐3A4 polymorphisms.